Kymab Ltd
https://www.kymab.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kymab Ltd
Stockwatch: Subdued Virtual J.P. Morgan Conference Prefaces Full-Year Earnings Season
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
UK Biotech Booms But Will It Ever Produce A Big Player?
Any chance that Kymab would advance to become a fully integrated biopharma has gone with Sanofi's deep pockets turning the heads of investors. Is the UK ever likely to develop its own Amgen or Moderna?
Sanofi Hits M&A Trail Again To Buy UK's KyMab
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics